Home > Insider Trading > Filing (0001209191-23-022376)

Filing Details

Accession Number:: 0001209191-23-022376
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-04-03 19:07:00
Reporting Period:: 2023-03-30

Accepted Time:: 2023-04-03 19:07:00
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1746473	Pliant Therapeutics Inc.	PLRX	Pharmaceutical Preparations (2834)	474272481

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1822619	Mike Ouimette	C/O Pliant Therapeutics, Inc. 260 Littlefield Avenue South San Francisco CA 94080	General Counsel & Corp. Sec'y	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2023-03-30	4,874	$26.52	53,666	No	4	S	Direct
Common Stock	Disposition	2023-04-03	2,677	$26.74	50,989	No	4	S	Direct
Common Stock	Disposition	2023-04-03	200	$27.46	50,789	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

Represents a nondiscretionary sale by the plan established on behalf of the Reporting Person on July 28, 2022 in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $25.88 to $27.235, inclusive, on March 30, 2023 and March 31, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2022.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.24 to $27.17, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2022.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.27 to $27.64, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4.